Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Health Minister to Kick Off Roundtable for Healthcare Policy for 2035 This Month
February 16, 2015
- PAFSC’s Second Committee to Discuss Celgene’s Multiple Myeloma Treatment Pomalidomide on Feb. 26
February 13, 2015
- PMDA Plans Manufacturing Inspections for 2 Regenerative Medicine Products This Year
February 12, 2015
- MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
- Health Minister Says to Mull Revising Generic Share Target
February 10, 2015
- National Cancer Center Announces Guidelines for Clinical Trial Monitoring and Auditing
February 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 26 - Feb. 8
February 9, 2015
- PAFSC 1st Committee to Discuss Actelion’s PAH Treatment on Feb. 20
February 9, 2015
- Panel OKs Intractable Disease Designation of Muscular Dystrophy
February 6, 2015
- NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
- MHLW Plans Business Suspension Order for Novartis
February 5, 2015
- R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
- Action to Be Taken against Novartis “Not Yet Decided”: Health Minister
February 4, 2015
- MHLW Calls for Suspension of Manufacturing, Import of Products Using Bovine-Derived Ingredients Originating in Norway
February 4, 2015
- Dr Fukui of St. Luke’s Tapped as Health Sciences Council Chair
February 3, 2015
- MHLW Compiles Requirements for Legally Recognized Clinical Research Core Hospitals
February 3, 2015
- Review Time Targets for New Drugs Revised: PFSB
February 3, 2015
- NIID to Evaluate Prototype Strains for Cell Culture-Based Influenza Vaccines
February 3, 2015
- MHLW Orders Package Insert Revision for Zytiga to Include Hypokalemia as Significant Adverse Reaction
February 3, 2015
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…